A comparison of the effects of cheese and butter on serum lipids, haemostatic variables and homocysteine

Anne S. Biong1,2, Hanne Müller3,4, Ingebjørg Seljeflot5, Marit B. Veierød6 and Jan I. Pedersen1,3*  

1Institute of Basic Medical Sciences, Department of Nutrition, University of Oslo, PO Box 1046 Blindern, 0316 Oslo, Norway  
2TINE Centre for Research and Development, 0902 Oslo, Norway  
3Akershus University College, 1356 Bekkestua, Norway  
4Department of Animal and Aquacultural Sciences, The Agricultural University of Norway, PO Box 5003, 1432 Ås, Norway  
5Centre for Clinical Research, Ullevål University Hospital, 0407 Oslo, Norway  
6Section of Medical Statistics, University of Oslo, 0317 Oslo, Norway  

(Received 3 February 2004 – Revised 17 June 2004 – Accepted 9 July 2004)

Milk fat contains considerable amounts of saturated fatty acids, known to increase serum cholesterol. Little is known, however, about the relative effect of different milk products on risk factors for CHD. The aim of the present study was to compare the effects of Jarlsberg cheese (a Norwegian variety of Swiss cheese) with butter on serum lipoproteins, haemostatic variables and homocysteine. A controlled dietary study was performed with twenty-two test individuals (nine men and thirteen women) aged 23–54 years. The subjects consumed three isoenergetic test diets, with equal amounts of fat and protein, and containing either cheese (CH diet), butter (BC diet) or butter + egg-white protein (BE diet). The study was a randomised cross-over study and the subjects consumed each diet for 3 weeks, with 1 week when they consumed their habitual diet in between. Fasting blood samples were drawn at baseline and at the end of each period. Serum was analysed for lipids and plasma for haemostatic variables and homocysteine. Total cholesterol was significantly lower after the CH diet than after the BC diet (−0.27 mmol/l; P=0.03), while the difference in LDL-cholesterol was found to be below significance level (−0.02 mmol/l; P=0.06). There were no significant differences in HDL-cholesterol, triacylglycerols, apo A-I, apo B or lipoprotein (a), haemostatic variables and homocysteine between the diets. The results indicate that, at equal fat content, cheese may be less cholesterol increasing than butter.

Coronary heart disease: Serum cholesterol: Dairy products: Fibrinolysis: Calcium

Milk fat is rich in saturated fat and cholesterol, known to increase serum cholesterol (Hegsted et al. 1993; Kris-Etherton & Yu, 1997). Populations with a high intake of saturated fat have a high CHD mortality (Renaud & Lanzmann-Petithory, 2001), and this is one reason why the intake of dairy products has been considered a main risk factor related to the high incidence of CHD in Western countries. However, the association between the intake of dairy products and the risk of CHD is somewhat controversial. Some observational studies have shown that diets rich in milk and butter are hypercholesterolaemic (Katan et al. 1995; Kushi et al. 1995; Pietinen et al. 1996; Moss, 2002) while others provide no convincing evidence that milk as such is harmful (Elwood et al. 2004). Others have even shown positive metabolic effects associated with the intake of dairy products (Smedman et al. 1999; Mennen et al. 2000; Ness et al. 2001; Pereira et al. 2002). One reason for this discrepancy may be that the populations studied consume different types of dairy products. For instance, in France with a low CHD mortality, cheese consumption is high, while in the Scandinavian countries with high CHD mortality, milk consumption is high.

Certain varieties of cheese are rich sources of saturated fat, which may be positively associated with an increased risk of heart disease (Hu et al. 1999), but some are also rich sources of Ca. Ca has been associated with a plasma lipid profile predictive of a lower risk of CHD (Jacqm air et al. 2003). Cheese is a fermented product, and it has been claimed that the consumption of fermented dairy products modulates cholesterol concentration (St Onge et al. 2000).

In addition, the bacteria involved in the ripening process may produce metabolites in the products, for instance folic acid (Forssen et al. 2000), that may affect serum homocysteine level (Appel et al. 2000). A high level of homocysteine in serum has been identified as a risk factor for CHD (Wald et al. 2002).

Abbreviations: BC, butter + calcium caseinate; BE, butter + egg-white protein; CH, cheese; FVII, factor VII coagulant activity; Lp (a), lipoprotein (a); PAI-1, plasminogen activator inhibitor type 1; TG, triacylglycerol; tPA, tissue plasminogen activator.

* Corresponding author: Professor Jan I. Pedersen, fax + 47 22 85 13 41, email j.i.pedersen@basalmmed.uio.no

British Journal of Nutrition (2004), 92, 791–797
© The Authors 2004
DOI: 10.1079/BJN20041257
Increased levels of markers of coagulation have been related to the development of CHD (Haverkate, 2002). Some studies have shown that haemostatic variables might be modified by diet (Marrkann, 2000), and it has been demonstrated in rats that butterfat in the diet may induce myocardial infarction from the thrombotic obstruction of coronary arteries (Thomas & Hartroft, 1959; Hornstra, 1985). Impairment of fibrinolysis from the intake of butterfat has also been described in human plasma (Mergan et al. 1959). On the other hand, in one observational study it was found that the consumption of dairy products was beneficially associated with markers of fibrinolysis (Mennen et al. 1999).

Studies specifically examining the effects of cheese intake on the risk of CHD are scarce (Tavani et al. 2002). Some ecological studies have shown weak and non-significant negative correlations between cheese intake and heart disease rates (Artaud-Wild et al. 1993; Moss & Freed, 2003). The potential relationship between cheese intake and traditional risk factors for CHD has, to our knowledge, been investigated only in one intervention study (Tholstrup et al. 2004) that indicated that cheese has a moderate cholesterol-lowering effect compared with butter. Thus, the present study was performed to further investigate the effect of cheese compared with butter on serum lipids, lipoproteins, homocysteine and haemostatic risk factors for CHD.

Methods

Subjects and study design

Thirty-three individuals, nine men and twenty-four women, were recruited among students at the University College of Akershus. Some of the subjects were also cohabitants of the students (n = 3), and relatives or friends of members of the project group (n = 3). Criteria for inclusion were that the participants should be reliable, without serious illness that could influence the results, and have a regular meal pattern. There were no screening criteria with regard to sex, age, smoking habits, physical activity or body weight. Body weight and height were measured, and BMI was calculated as weight (kg)/height (m)². Body weight in the fasting state was measured at baseline, and after each intervention period, and also in the non-fasting state before dinner twice weekly. A food-frequency questionnaire was filled in by the subjects and showed that all subjects had ordinary dietary habits. A questionnaire about physical activity was filled in to calculate the subjects’ energy level. Some participants used medications: drugs against asthma (n = 2), allergy (n = 3), menopausal problems (n = 1), depression (n = 1) and epilepsy (n = 1). Two participants used oral contraceptives.

The study was a randomised three-period cross-over study which started in September 2001 and ended in December 2001. The participants were randomised into three groups and received three strictly controlled diets during periods of 3 weeks each. The diets contained three different test components: (A) cheese (CH diet), (B) butter + casein (as calcium caseinate) (BC diet) and (C) butter + egg-white (BE diet), consumed in one of three sequences (ABC, BCA, CAB). The intervention periods were separated by a 1-week period when subjects ate their habitual diet. The participants were requested to maintain their levels of physical activity and their smoking habits during the study, and were told to abstain from alcohol consumption. No payment was given, but the participants received free food. The study was performed in accordance with the Helsinki Declaration and the study protocol was approved by the Regional Committee for Ethics in Biomedical Research. All participants gave their written, informed consent.

Experimental diets

Three diets were designed by using a computer-based, nutrient-calculation program (‘Mat på data’ 3.0c; the National Association for Nutrition and Health, Oslo, Norway). The three test diets were isoenergetic, based on traditional Norwegian food, and consisted of a carefully planned, 7 d recycling menu of four main meals per d. They were designed to have the same nutrient composition, and were calculated to contain 28 % energy from fat, 26 % energy from protein and 46 % energy from carbohydrate. Of the fat, 20 % energy came from the dairy product under study, and 8 % energy from sources other than the test fat. Menus for the three experimental diets contained the same basic food items; meat, fish, bread, vegetables, fruit etc. They were all identical except for the different test component. The cheese was a Norwegian Swiss-type cheese (‘Jarlsberg’) which was taken from the production line. It was consumed 3–5 months after the production day. The bacteria strains used in the fermentation of Jarlsberg cheese are: Lactococcus lactis subsp. cremoris, L. lactis subsp. lactis, L. lactis subsp. lactis biovar diacetylactis, Leuconostoc mesenteroides subsp. cremoris and Propionibacterium freudenreichii. The casein used was in the form of calcium caseinate powder, and the egg-white was also in the form of powder. All were ordinary products produced for the market. The test components (cheese, butter, calcium caseinate and egg-white) were supplied to the menus as spreads, bread and sauce.

Dinner was for most of the participants eaten at the school kitchen during weekdays, whereas pre-packed breakfasts, lunches, snacks, and weekend meals were supplied to be eaten at home. No foods other than those provided were allowed during the controlled feeding periods. Tea and mineral water with artificial sweeteners were allowed. Coffee was allowed in restricted amounts (not more than two cups/d). The subjects were supplied with free food to meet 100 % of their daily energy requirements. The diets were served according to five different energy levels; 7.5, 8, 10, 12.5, and 15 MJ. The intake of cheese and butter on the 8 MJ diets was 150 and 52 g/d, respectively, which corresponds to a fat intake from cheese or butter of 42 g/d.

Duplicate portions corresponding to an energy intake of 8 MJ were collected of all three diets for 7 d and kept at −20°C until they were homogenised and freeze-dried. The seven homogenates from each diet were pooled and samples of the three diets were analysed for their content of fat, protein, cholesterol, Ca and fatty acid composition.
Chemical analysis

The content of total fat in the duplicate portions was determined by chloroform–methanol extraction (Folch et al. 1957). The N content was determined by the Kjeldahl technique. The factor used for the conversion of N content to protein was 6·30. The extracted fatty acids from the duplicate portions were methylated with benzene and methanolic HCl (3 m) using the method of Hoshi et al. (1973) and analysed by GC.

Blood sampling and analysis

Blood samples were drawn after an overnight fast immediately before breakfast at baseline and twice (on two following days) at the end of each diet period. The mean of the two values from the end of each period was used. Baseline blood samples were not drawn for the analysis of lipoprotein (a) (Lp (a)) and haemostatic variables. Blood samples were drawn with minimal stasis using the Vacutainer system and analysed for lipids, haemostatic variables and homocysteine. All samples from a given individual were analysed in the same batch.

Serum for lipid analyses was obtained by centrifugation at 2500g for 15 min at 4°C within 1 h of venepuncture and stored at −70°C until analysed. Total cholesterol and triglycerides (TG) was measured by enzymic methods using commercial kits (Technicon reagent T01-1684-02 and Technicon reagent T01-1868-02; Bayer, Tarrytown, NY, USA). Serum HDL-cholesterol was measured directly by a detergent-containing method. This detergent solubilises only HDL while non-HDL lipoproteins are inhibited from reacting with the enzymes (Liquid N-GENEous HDL-c reagent; Genzyme Diagnostics, West Malling, Kent, UK). All the lipid analyses were spectrophotometric, using automated analyser equipment (Technicon RA 1000; Tarrytown, NY, USA). The interassay CV were as follows (%): total cholesterol, 0·9; HDL, 2·4; TG, 1·5. Serum LDL-cholesterol was calculated using the Friedewald equation (Friedewald et al. 1972). Serum apo A-I and apo B were both quantified by an immunochromatographic method and measured by nephelometry (N antisera to human apo A-I and apo B; Dade Behring Marburg GmbH, Marburg, Germany) with CV of 4·5 and 4·6% respectively. Lp (a) was quantified by a commercial kit (TintElize Lp (a); Biopool AB, Umeå, Sweden) according to the manufacturer’s instructions. The interassay CV was 2·7%.

Citrated plasma for analyses of the fibrinolytic factors plasminogen activator inhibitor type 1 (PAI-1) activity, PAI-1 antigen, t-PA activity and t-PA antigen were measured using commercially available kits (Spectrolyse/pl, TintElize PAI-1, Chromolize tPA and TintElize tPA, respectively; Biopool AB, Umeå, Sweden). FVII was measured using a commercially available chromogenic assay (COASET FVII; Chromogenix, Chromogenix-Instrumentation Laboratory SpA, Milan, Italy). Fibrinogen was measured according to Clauss (1957) using an ACL-3000 Coagulation system Analyser (Instrumentation Laborator, Milan, Italy). Prothrombin fragment 1 + 2 was measured by an enzyme immunosassay (Enzygnost F1 + 2 micro; Behringwerke AG, 35001 Marburg, Germany). Interassay CV were as follows (%): tPA antigen, 3·5; tPA activity, 8·0; PAI-1 antigen, 9·8; PAI-1 activity, 4·8; fibrinogen, 3·6; FVII, 3·1; prothrombin fragment 1 + 2, 8·2.

Plasma for homocysteine analyses was obtained by centrifugation at 1800g for 10 min at 4°C directly after venepuncture and stored at −70°C until analysed. Heparin was used as an anticoagulant. Total homocysteine (free and protein-bound) was determined by HPLC using a commercial kit from Bio-Rad (Bio-Rad Laboratories GmbH, Munich, Germany). The interassay CV was 5%.

Statistical methods

The results are presented as mean values and standard deviations. To compare the effects of the three diets, repeated measures ANOVA was applied (general linear model univariate procedure in SPSS). In addition to diet, period was included in the models to test for systematic differences between the three intervention periods. No period effects were found, thus this was removed from the models. When a statistically significant effect of diet was found, pair-wise comparisons between the three diets were performed with the Bonferroni correction. Plasma Lp (a) and tPA antigen were log2-transformed. All P values are two-sided, and a 5% level of significance was used. All data analyses were performed with SPSS version 11.0 (SPSS Inc., Chicago, IL, USA).

Results

Subjects

Of the thirty-three individuals recruited, six dropped out at the start of the study either because they disliked the diet or because of personal practical problems. Three more withdrew during the first period because of family illness and compliance problems. The remaining twenty-four individuals, nine men and fifteen women, mean age 31·5 (range 21·5–54 years), participated in the study. The mean BMI was 27 (range 19–37) kg/m2 and their mean waist:hip ratio was 0·8 (range 0·7–1·0). The results from two individuals had to be excluded because of unacceptable weight loss. The final analyses are thus based on the results from twenty-two individuals. Compliance with the diets was judged by direct observation of the consumption of weekday dinners, and by the evaluation of food diaries. The mean fasting body weights after each of the three dietary periods did not differ notably (CH diet 78·1 (SD 17·2) kg, BC diet 78·1 (SD 17·0) kg, BE diet 77·8 (SD 17·1) kg).
Test diets

The results of duplicate portions of the three diets are given in Table 1. The energy content was somewhat higher than the calculated 8 MJ. The proportions of fat in the diets were slightly lower than originally calculated in the CH and BC diets, and the proportion of protein was slightly higher than calculated in the CH diet. The content of Ca was not calculated when the diets were planned, and differed in the three diets with the highest intake from the CH diet (2108 mg/d) and the lowest intake from the BE diet (830 mg/d).

The fatty acid compositions of the test diets are shown in Table 2. The three diets contained similar amounts of the different fatty acids. Of all fatty acids, 60.5% were saturated, 29% monounsaturated and 10.5% polyunsaturated.

Serum lipids and lipoproteins

The concentrations of total, LDL- and HDL-cholesterol, the total cholesterol:HDL-cholesterol ratio, TG, apo A-I, apo B and Lp (a) at baseline and after the three test diets are shown in Table 3. Lp (a) was not analysed at baseline. Only total cholesterol concentration was significantly different between the diets \((P=0.04)\). We found a significantly lower level after the CH period than after the BC period (difference between means \(-0.27 (95\% CI -0.52, -0.015)\) mmol/l; \(P=0.03\)). The results also showed a reduction in LDL-cholesterol after the CH diet compared with the BC diet, but this result was not significant (difference between means \(-0.22 (95\% CI -0.44, 0.00)\) mmol/l; \(P=0.06\)).

Haemostatic variables and homocysteine

The concentrations of haemostatic variables and homocysteine at baseline and after the three test diets are shown in Table 4. Baseline values for tPA activity, tPA antigen, PAI-1 activity, PAI-1 antigen, FVII, fibrinogen and prothrombin fragment 1 + 2 were not analysed. The only haemostatic variable showing a significant difference between the diets was fibrinogen \((P=0.04)\). However, one subject had an extremely high fibrinogen level on the CH diet compared with the BC and BE diets, and when the results from this subject were excluded from the dataset, no significant difference was found between the diets \((P=0.12)\). There was no significant difference in homocysteine levels between the diets \((P=0.14; \text{Table 4})\).

Discussion

The results from the present strictly controlled dietary study indicate that, at equal fat content, cheese may be less cholesterol increasing than butter. The LDL:HDL ratio, however, showed no difference between the diets. When haemostatic variables and homocysteine are considered, the results from the present study do not show any beneficial effect from cheese compared with butter.

As far as we know, only one similar intervention study comparing the effects of cheese and butter on CHD risk factors has been published previously (Tholstrup et al. 2004). Also in that study, on fourteen healthy young men, the intake of a cheese diet resulted in \(0.21\) mmol/l lower LDL-cholesterol than the intake of a butter diet \((P=0.037)\), with a borderline significant difference in total cholesterol \((0.20\) mmol/l; \(P=0.054)\).

Only a few ecological and observational studies have investigated the association between the intake of cheese and the risk of CHD, and the results from these studies are contradictory. The Oxford Vegetarian Study, a prospective cohort study, showed a positive association between the intake of cheese and total cholesterol in both men and women, and also a positive association between the intake of cheese and IHD mortality in vegetarians (Appleby et al. 1999). Moss & Freed (2003) reported in their ecological study a strong positive correlation between milk-consumption figures for 1989 and heart disease death rates in 1993 in some Organisation for Economic Co-operation and Development countries, while cheese intake was...
non-significantly negatively correlated. Furthermore, a case–control study conducted in Italy reported that men and women in the highest tertile for cheese intake were no more likely to have had a myocardial infarction than individuals in the lowest tertile (Tavani et al. 2002). In an observational study from Sweden, a significant negative association was found between the intake of cheese and serum cholesterol levels among adolescent boys (Samuelsson et al. 2001).

In the present study the three diets differed in Ca with the highest intake from the CH diet (2108 mg/d), the lowest from the BE diet (830 mg/d) and the BC diet in between (1143 mg/d) (Table 1). One possible mechanism behind the present findings could be that dietary Ca promotes the excretion of fat as Ca soaps in faeces (Renaud & Lanzmann-Petithory, 2001; Lorenzen et al. 2004). Our diets were not balanced in Ca content for the reason that we were interested in investigating the effect of cheese and butter as food products, and not single nutrients, on risk factors for CHD. Yacowitz et al. (1965) showed a significant decrease in both serum cholesterol and TG levels in subjects with an increased ingestion of Ca, and could furthermore demonstrate an increase in total faecal lipids. Also Bhattacharyya et al. (1969) found a significant decrease in serum cholesterol after the intake of a high-Ca high-saturated-fat diet compared with a low-Ca high-saturated-fat diet.

St Onge et al. (2000) examined the available literature supporting the claim that the consumption of fermented dairy products modulates cholesterol concentrations and found a moderate cholesterol-lowering action of such products. In that review some possible mechanisms behind the findings are pointed out. One necessary condition is that the bacteria are able to survive the gut and colonise the intestine (i.e. be probiotic). Once in the large intestine, bacteria ferment indigestible carbohydrates and produce SCFA.

### Table 3. Serum lipoprotein levels at baseline and at the end of the dietary test periods for twenty-two participants†

<table>
<thead>
<tr>
<th></th>
<th>CH diet</th>
<th>BC diet</th>
<th>BE diet</th>
<th>P value†</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline mean</strong></td>
<td>Mean</td>
<td>Mean</td>
<td>Mean</td>
<td>Mean</td>
</tr>
<tr>
<td><strong>Total cholesterol (mmol/l)</strong></td>
<td>5·55</td>
<td>5·40*</td>
<td>5·55</td>
<td>0·04</td>
</tr>
<tr>
<td><strong>LDL-cholesterol (mmol/l)</strong></td>
<td>3·61</td>
<td>3·57</td>
<td>3·78</td>
<td>0·06</td>
</tr>
<tr>
<td><strong>HDL-cholesterol (mmol/l)</strong></td>
<td>1·47</td>
<td>1·39</td>
<td>1·44</td>
<td>0·11</td>
</tr>
<tr>
<td><strong>LDL-cholesterol/HDL-cholesterol</strong></td>
<td>2·53</td>
<td>2·63</td>
<td>2·71</td>
<td>0·28</td>
</tr>
<tr>
<td><strong>Triacylglycerols (mmol/l)</strong></td>
<td>1·07</td>
<td>0·98</td>
<td>0·98</td>
<td>0·22</td>
</tr>
<tr>
<td><strong>Apo A1 (g/l)</strong></td>
<td>1·56</td>
<td>1·40</td>
<td>1·45</td>
<td>0·06</td>
</tr>
<tr>
<td><strong>Apo B (g/l)</strong></td>
<td>0·93</td>
<td>0·92</td>
<td>0·96</td>
<td>0·33</td>
</tr>
<tr>
<td><strong>Lipoprotein (a) (mg/l)</strong></td>
<td>−4</td>
<td>−156</td>
<td>−143</td>
<td>0·16§</td>
</tr>
</tbody>
</table>

* Mean value was significantly different from that after the BC diet (P = 0·03).
† For details of diets and procedures, see Tables 1 and 2 and p. 793.
‡ Evidence of diet (repeated measures ANOVA).
§ The analysis was performed on loge-transformed data.
|| Baseline value for lipoprotein (a) was not analysed.

### Table 4. Haemostatic variables and homocysteine levels at baseline and at the end of the dietary test periods for twenty-two participants*

<table>
<thead>
<tr>
<th></th>
<th>CH diet</th>
<th>BC diet</th>
<th>BE diet</th>
<th>P value†</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline mean†</strong></td>
<td>Mean</td>
<td>Mean</td>
<td>Mean</td>
<td>Mean</td>
</tr>
<tr>
<td><strong>tPA activity (IU/ml)</strong></td>
<td>0·92</td>
<td>0·78</td>
<td>0·96</td>
<td>0·63</td>
</tr>
<tr>
<td><strong>tPA antigen (ng/ml)</strong></td>
<td>6·0</td>
<td>6·2</td>
<td>6·1</td>
<td>0·23§</td>
</tr>
<tr>
<td><strong>PAI-1 activity (U/ml)</strong></td>
<td>10·6</td>
<td>13·0</td>
<td>10·2</td>
<td>0·21</td>
</tr>
<tr>
<td><strong>PAI-1 antigen (ng/ml)</strong></td>
<td>13·6</td>
<td>14·8</td>
<td>12·8</td>
<td>0·57</td>
</tr>
<tr>
<td><strong>Factor VIIc (%)</strong></td>
<td>100</td>
<td>101</td>
<td>104</td>
<td>0·69</td>
</tr>
<tr>
<td><strong>Fibrinogen (g/l)</strong></td>
<td>2·67</td>
<td>2·55</td>
<td>2·50</td>
<td>0·04</td>
</tr>
<tr>
<td><strong>Prothrombin fragment 1 + 2 (nmol/l)</strong></td>
<td>0·78</td>
<td>0·65</td>
<td>0·80</td>
<td>0·41</td>
</tr>
<tr>
<td><strong>Homocysteine (µmol/l)</strong></td>
<td>9·34</td>
<td>8·82</td>
<td>8·41</td>
<td>0·14</td>
</tr>
</tbody>
</table>

* For details of diets and procedures, see Tables 1 and 2 and p. 793.
† Baseline values for tPA activity, tPA antigen, PAI-1 activity, PAI-1 antigen, factor VIIc, fibrinogen and prothrombin fragment 1 + 2 were not analysed.
‡ Evidence of diet (repeated measures ANOVA).
§ The analysis was performed on loge-transformed data.
|| P = 0·12 after exclusion of one subject with an extremely high level of fibrinogen after the CH diet (see p. 794).
which are absorbed and influence cholesterol metabolism in the liver (Wolever et al. 1996). Also, the intestinal bacteria can bind bile acids to cholesterol, resulting in the excretion of bile acid–cholesterol complexes in the faeces (St Onge et al. 2000).

Many probiotic bacterial strains have been investigated for their cholesterol-lowering potential, but the results are inconclusive (de Roos & Katan, 2000). One of the bacterial strains used in the fermentation of Jarlsberg cheese, L. lactis subsp. cremoris, was found to have a hypocholesterolaemic effect in rats when skimmed milk fermented with this bacterial strain was compared with chemically acidified skimmed milk (Nakajima et al. 1992). Whether this strain can survive the gut and colonise the intestine in man is not known. The propionic acid bacteria are shown to adhere to the intestinal epithelial tissue (Zarate et al. 2002), and P. freudenreichii, the propionic acid bacterial strain used in Swiss-type cheeses has also been shown to stay alive through the gut (Ouwehand et al. 2001) and may exert an effect in the intestine. The propionic acid bacteria (P. shermanii subsp. freudenreichii INF-a) used in Jarlsberg cheese has never been tested for probiotic properties or cholesterol-lowering potential.

Casein, the main protein in milk and dairy foods, is reported to be hypercholesterolaemic when substituted for soya protein, although the effect of casein on blood cholesterol levels varies widely in different studies and appears to depend on experimental conditions (Forsythe et al. 1986). In the present study, the content of protein, and thereby casein, was higher in the CH diet than in the BC diet, so the cholesterol-increasing effect of the BC diet can not be explained by the content of casein.

As far as we know, only one study has investigated the association between haemostatic variables and the intake of cheese. Mennen et al. (1999) reported from a prospective cohort study an inverse association between haemostatic variables and the intake of cheese, and the Norwegian Meat Marketing Board and TINE BA, that also provided milk, yoghurt, butter and cheese, and the Norwegian Meat Marketing Board and Fellesjuice AS that provided juice products.

Casein, the main protein in milk and dairy foods, is reported to be hypercholesterolaemic when substituted for soya protein, although the effect of casein on blood cholesterol levels varies widely in different studies and appears to depend on experimental conditions (Forsythe et al. 1986). In the present study, the content of protein, and thereby casein, was higher in the CH diet than in the BC diet, so the cholesterol-increasing effect of the BC diet can not be explained by the content of casein.

As far as we know, only one study has investigated the association between haemostatic variables and the intake of cheese. Mennen et al. (1999) reported from a prospective cohort study an inverse association between haemostatic variables and the intake of cheese, and the Norwegian Meat Marketing Board and TINE BA, that also provided milk, yoghurt, butter and cheese, and the Norwegian Meat Marketing Board and Fellesjuice AS that provided juice products.

Further studies are needed to verify the present results and to elucidate the possible mechanisms behind the present findings of the differential effects on serum cholesterol of cheese and butter.

Acknowledgements

We gratefully acknowledge the cooperation of the participants in the study. We thank Anntjørg Lindbäck, Anja Schou Lindman, and the kitchen staff for their assistance, Bente Braathen and Turid Veggan for drawing and handling the blood samples, and Anne Randi Alvestad for drawing and handling the blood samples and for help with the lipid analyses. The study was supported financially by the Research Council of Norway, the dairy company TINE BA, that also provided milk, yoghurt, butter and cheese, and the Norwegian Meat Marketing Board and Fellesjuice AS that provided juice products.

References


Cheese, butter and coronary heart disease 797